Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 14/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206815 | 0.86 | MAP2K1 (0.51) | MAP2K1MAP2K2PIM1 | |
| SCHEMBL391367 | 0.81 | MAP2K1 (0.59) | MAP2K1MAP2K2 | |
| SCHEMBL3424014 | 0.80 | DGAT1 (0.34) | MAP2K1DGAT1MAP2K2PIM1PIM3 | |
| SCHEMBL5404404 | 0.79 | MAP2K1 (0.36) | MAP2K1DGAT1MAP2K2TP53 | |
| SCHEMBL6137572 | 0.78 | MAP2K1 (0.40) | MAP2K1MAP2K2PIM1PIM3PIM2 | |
| SCHEMBL5474880 | 0.78 | DGAT1 (0.40) | MAP2K1DGAT1MAP2K2TP53MAPT | |
| SCHEMBL394009 | 0.76 | MAP2K1 (0.55) | MAP2K1MAP2K2 | |
| SCHEMBL6207380 | 0.74 | TUBB4A (0.31) | MAP2K1MAP2K2 | |
| SCHEMBL5406374 | 0.74 | MAP2K1 (0.36) | MAP2K1DGAT1MAP2K2TP53MAPT | |
| SCHEMBL3972766 | 0.73 | MAP2K1 (0.35) | MAP2K1DGAT1MAP2K2NOTUMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9707275-B2 | Stable aqueous composition comprising human insulin or an analogue or derivative thereof | WOCKHARDT LIMITED (IN) | 2017-07-18 | — | — | US | claimed |
| US-20150265683-A1 | Stable aqueous composition comprising human insulin or an analogue or derivative thereof | WOCKHARDT LTD (IN) | 2015-09-24 | — | — | US | claimed |
| WO-2014096985-A2 | A STABLE AQUEOUS COMPOSITION COMPRISING HUMAN INSULIN OR AN ANALOGUE OR DERIVATIVE THEREOF | WOCKHARDT LIMITED (IN) | 2014-06-26 | — | — | WO | claimed |
| EP-1578736-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| WO-2004056789-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | claimed |
| US-20230330727-A1 | Compositions and Methods for Cleaning Contaminated Solids and Liquids | FRANSSEN TODD (US) | 2023-10-19 | — | — | US | disclosed |
| US-11724293-B2 | Compositions and methods for cleaning contaminated solids and liquids | FRANSSEN TODD (US) | 2023-08-15 | — | — | US | disclosed |
| US-20210162476-A1 | Compositions and Methods for Cleaning Contaminated Solids and Liquids | FRANSSEN TODD (US) | 2021-06-03 | — | — | US | disclosed |
| US-10906075-B2 | Compositions and methods for cleaning contaminated solids and liquids | FRANSSEN TODD (US) | 2021-02-02 | — | — | US | disclosed |
| US-20180361444-A1 | Compositions and Methods for Cleaning Contaminated Solids and Liquids | FRANSSEN TODD (US) | 2018-12-20 | — | — | US | disclosed |
| US-10065224-B2 | Compositions and methods for cleaning contaminated solids and liquids | FRANSSEN TODD (US) | 2018-09-04 | — | — | US | disclosed |
| US-9707275-B2 | Stable aqueous composition comprising human insulin or an analogue or derivative thereof | WOCKHARDT LIMITED (IN) | 2017-07-18 | — | — | US | disclosed |
| WO-1996016132-A1 | CLEANING COMPOSITIONS AND METHODS OF USING THE SAME | KAY CHEMICAL COMPANY (US) | 1996-05-30 | — | — | WO | disclosed |
| EP-0607198-A1 | PREPARATION OF IMPROVED ALKYLPOLYGLYCOSIDE SURFACTANT MIXTURES | HENKEL CORPORATION (US) | 1994-07-27 | — | — | EP | disclosed |
| EP-0601165-A1 | AQUEOUS FLOWABLE PHENAZAQUIN COMPOSITION | DOWELANCO (US) | 1994-06-15 | — | — | EP | disclosed |
| WO-1993024005-A1 | AQUEOUS FLOWABLE PHENAZAQUIN COMPOSITION | DOWELANCO (US) | 1993-12-09 | — | — | WO | disclosed |
| US-5242615-A | Anionic and amphoteric surfactant compositions with reduced viscosity | HENKEL CORPORATION (US) | 1993-09-07 | — | — | US | disclosed |
| WO-1993007249-A1 | PREPARATION OF IMPROVED ALKYLPOLYGLYCOSIDE SURFACTANT MIXTURES | HENKEL CORPORATION (US) | 1993-04-15 | — | — | WO | disclosed |
| WO-1991004313-A1 | ANIONIC AND AMPHOTERIC SURFACTANT COMPOSITIONS WITH REDUCED VISCOSITY | HENKEL CORPORATION (US) | 1991-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | MAP2K1 46/4885DGAT1 1846/4885MAP2K2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.